These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9082841)

  • 21. Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors.
    Uckert S; Bazrafshan S; Scheller F; Mayer ME; Jonas U; Stief CG
    Urology; 2007 Jul; 70(1):185-9. PubMed ID: 17656245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease].
    Szapáry L; Horváth B; Alexy T; Márton Z; Késmárky G; Szóts M; Nagy F; Czopf J; Tóth K
    Orv Hetil; 2003 May; 144(20):973-8. PubMed ID: 12830727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanism of the vasodilator action of kavinton on the cerebral vessels].
    Plotnikov MB; Kotov AN
    Farmakol Toksikol; 1983; 46(6):36-9. PubMed ID: 6653756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies].
    Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöczk P; Farde L
    Orv Hetil; 1999 Jul; 140(30):1687-91. PubMed ID: 10461449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigation of vasoactive agents with indole skeletons at Richter Ltd].
    Kárpáti E; Bíró K; Kukorelli T
    Acta Pharm Hung; 2002; 72(1):25-36. PubMed ID: 12426785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
    Dunkern TR; Hatzelmann A
    FEBS J; 2007 Sep; 274(18):4812-24. PubMed ID: 17697115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models].
    Pereira C; Agostinho P; Moreira PI; Duarte AI; Santos MS; Oliveira CR
    Acta Med Port; 2003; 16(6):401-6. PubMed ID: 15631851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
    Muravyov AV; Bulaeva SV; Tikhomirova IA; Zamishlayev AV; Uzikova EV; Miloradov MJ
    Clin Hemorheol Microcirc; 2011; 49(1-4):431-9. PubMed ID: 22214714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo.
    Nekrassov V; Sitges M
    Epilepsy Res; 2004 Jun; 60(1):63-71. PubMed ID: 15279871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat.
    Nossaman BD; Bivalacqua TJ; Champion HC; Baber SR; Kadowitz PJ
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):358-66. PubMed ID: 18049302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies].
    Bagoly E; Fehér G; Szapáry L
    Orv Hetil; 2007 Jul; 148(29):1353-8. PubMed ID: 17631470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation.
    Chen RW; Williams AJ; Liao Z; Yao C; Tortella FC; Dave JR
    Neurosci Lett; 2007 May; 418(2):165-9. PubMed ID: 17398001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes.
    Tretter L; Adam-Vizi V
    Neuroreport; 1998 Jun; 9(8):1849-53. PubMed ID: 9665614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of kavinton on systemic and regional hemodynamics in waking and anesthetized rats].
    Ivashev MN; Martynova ER; Medvedev OS
    Farmakol Toksikol; 1989; 52(1):26-9. PubMed ID: 2707414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vinpocetin in neurological diseases].
    Szapáry L; Késmárky G; Tóth K; Misnyovszky M; Tóth T; Balogh A; Nagy K; Németh GY; Fehér G
    Ideggyogy Sz; 2012 Nov; 65(11-12):387-93. PubMed ID: 23289173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients.
    Kemény V; Molnár S; Andrejkovics M; Makai A; Csiba L
    J Clin Pharmacol; 2005 Sep; 45(9):1048-54. PubMed ID: 16100299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences.
    Vas A; Gulyás B; Szabó Z; Bönöczk P; Csiba L; Kiss B; Kárpáti E; Pánczél G; Nagy Z
    J Neurol Sci; 2002 Nov; 203-204():259-62. PubMed ID: 12417394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vinpocetine. Monograph.
    Altern Med Rev; 2002 Jun; 7(3):240-3. PubMed ID: 12126465
    [No Abstract]   [Full Text] [Related]  

  • 39. Protective effect of vinpocetine against brain damage caused by ischemia.
    Rischke R; Krieglstein J
    Jpn J Pharmacol; 1991 Jul; 56(3):349-56. PubMed ID: 1895579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation.
    Zhuplatov SB; Masaki T; Blumenthal DK; Cheung AK
    Basic Clin Pharmacol Toxicol; 2006 Dec; 99(6):431-9. PubMed ID: 17169124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.